Welcome back to the Oncology Brothers podcast! In this episode, we dived into the latest highlights from the EHA 2026 conference, focusing on groundbreaking studies in the leukemia space.

Join us as we welcome Dr. Eunice Wang from Roswell Park Comprehensive Cancer Center to discuss three pivotal studies:

OPTI-AML: explored the findings on the use of venetoclax in combination with azacitidine for newly diagnosed AML patients, comparing 14-day versus 28-day treatment regimens and their impact on cytopenias and overall outcomes.
KOMET-007: promising early data on menin inhibitors, specifically Ziftomenib, in frontline settings for patients with NPM1 and KMT2A rearrangements, and how it may change the landscape of AML treatment.
SENTRY: analyzed the combination of ruxolitinib and selinexor for myelofibrosis, discussing its effects on spleen volume reduction and overall survival, as well as the implications of side effects.

Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o

Follow us on social media: •⁠ ⁠X/Twitter: https://x.com/oncbrothers •⁠ ⁠Instagram: https://www.instagram.com/oncbrothers •⁠ Website: https://oncbrothers.com/

Tune in for an insightful discussion on the future of leukemia treatment and the importance of genetic markers in therapy decisions. Don't forget to like, subscribe, and check out our other conference highlights from ASCO and EHA!

#EHA2026, #Leukemia, #AML, #Myelofibrosis, #OncologyBrothers

EHA2026 Leukemia Highlights: OPTI-AML, KOMET-007, SENTRY

Oncology Brothers: Practice-Changing Cancer Discussions

EHA2026 Leukemia Highlights: OPTI-AML, KOMET-007, SENTRY